

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/05491

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 A61K31/495 A61P37/00

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, MEDLINE, BIOSIS, EMBASE, CHEM ABS Data

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 06429 A (SEPRACOR INC) 31 March 1994 (1994-03-31) cited in the application page 1-7 page 15 page 20 -page 21	1-9
X	"Xyzal (Levocetirizine) launched in England for Allergic Rhinitis" INTERNET, 'Online! 1 October 2001 (2001-10-01), XP002240083 Retrieved from the Internet: <URL:http://www.pslgroup.com/dg/207766.htm http://www.pslgroup.com/dg/207766.htm> 'retrieved on 2003-05-05! the whole document	1-9

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 September 2003

Date of mailing of the international search report

23/09/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Domingues, H

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/05491

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>"Germany Approves Antihistamines Xyza1"  INTERNET, 'Online!  16 January 2001 (2001-01-16), XP002240084  Retrieved from the Internet:  &lt;URL:http://www.pslgroup.com/dg/lefc66.htm  http://www.pslgroup.com/dg/lefc66.htm&gt;  'retrieved on 2003-05-05!  the whole document</p>	1-9
X	<p>GENSTHALER BM: "Levocetirizine:  R-enantiomer against allergies"  PHARMAZEUTISCHE ZEITUNG,  vol. 146, no. 7,  15 February 2001 (2001-02-15), pages  35-36, XP001147797  page 35  page 35 -page 36</p>	1-9
Y	<p>GRANT J ANDREW ET AL: "A double-blind,  randomized, single-dose, crossover  comparison of levocetirizine with  ebastine, fexofenadine, loratadine,  mizolastine, and placebo: suppression of  histamine-induced wheal-and-flare response  during 24 hours in healthy male subjects."  ANNALS OF ALLERGY, ASTHMA &amp; IMMUNOLOGY:  OFFICIAL PUBLICATION OF THE AMERICAN  COLLEGE OF ALLERGY, ASTHMA, &amp; IMMUNOLOGY.  UNITED STATES FEB 2002,  vol. 88, no. 2, February 2002 (2002-02),  pages 190-197, XP009010299  ISSN: 1081-1206  abstract  page 195 -page 196</p>	1-9
Y	<p>GANDON J M ET AL: "Lack of effect of  single and repeated doses of  levocetirizine, a new antihistamine drug,  on cognitive and psychomotor functions in  healthy volunteers."  BRITISH JOURNAL OF CLINICAL PHARMACOLOGY,  vol. 54, no. 1, July 2002 (2002-07), pages  51-58, XP002240086  e=bjcp July, 2002  ISSN: 0306-5251  abstract  page 52  page 56 -page 58</p>	1-9

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/05491

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9406429	A	31-03-1994	AT 170749 T	15-09-1998
			AU 4932093 A	12-04-1994
			AU 711212 B2	07-10-1999
			AU 5934398 A	21-05-1998
			CA 2145410 A1	31-03-1994
			DE 69320975 D1	15-10-1998
			DE 69320975 T2	12-05-1999
			DK 663828 T3	07-06-1999
			EP 0663828 A1	26-07-1995
			EP 0950412 A2	20-10-1999
			ES 2122042 T3	16-12-1998
			JP 8501561 T	20-02-1996
			LU 90898 A9	08-04-2002
			WO 9406429 A1	31-03-1994
			US 5698558 A	16-12-1997

---